Literature DB >> 28676915

Characterization of the new human pleomorphic undifferentiated sarcoma TP53-null cell line mfh-val2.

Rosario Gil-Benso1, Javier Megías2, Teresa San-Miguel2, Sandra Pinto3, Robert C Callaghan2, Concha López-Ginés2, Miguel Cerdá-Nicolás2,4.   

Abstract

Pleomorphic undifferentiated sarcoma (PUS), also called malignant fibrous histiocytoma, is a soft tissue sarcoma which occurs predominantly in the extremities. Its origin is a poorly defined mesenchymal cell, which derives to histiocytic and fibroblastic cells. The patient, a 58 year-old man, presented a lesion located in the forearm composed by spindle cells and multinucleated giant cells, which expressed vimentin and adopted a histological pattern formed by irregular-swirling fascicles. Cells were cultured in vitro and a new cell line was established. We characterized this new cell line by histological analyses, cytogenetics (using G-bands and spectral karyotype technique) and cytometric analyses. Cells were grown in culture for more than 100 passages. They had elongated or polygonal morphology. The cells presented a saturation rate of 70,980 cells/cm2, a plating efficiency of 21.5% and a mitotic index of 21 mitoses per field. The cell line was tumorigenic in nude mice. The ploidy study using flow cytometry revealed an aneuploid peak with a DNA index of 1.43. A side population was detected, demonstrating the presence of stem and progenitor cells. Cytogenetics showed a hypotriploid range with many clonal unbalanced rearrangements. Loss of p53 gene was evidenced by MLPA. We describe, for the first time, the characterization of a new human PUS TP53-null cell line called mfh-val2. Mfh-val2 presents a wide number of applications as a TP53-null cell line and a great interest in order to characterize genetic alterations influencing the oncogenesis or progression of PUS and to advance in the biological investigation of this tumor.

Entities:  

Keywords:  Cell line; Malignant fibrous histiocytoma; Pleomorphic undifferentiated sarcoma; TP53-null

Year:  2017        PMID: 28676915      PMCID: PMC5507838          DOI: 10.1007/s10616-017-0112-5

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  43 in total

1.  Benefits of bad telomeres.

Authors:  D Hanahan
Journal:  Nature       Date:  2000-08-10       Impact factor: 49.962

2.  Characterization of a new human melanoma cell line with CD133 expression.

Authors:  Rosario Gil-Benso; Carlos Monteagudo; Miguel Cerdá-Nicolás; Robert C Callaghan; Sandra Pinto; Alicia Martínez-Romero; Ana Pellín-Carcelén; Teresa San-Miguel; Juan C Cigudosa; Concha López-Ginés
Journal:  Hum Cell       Date:  2012-04-13       Impact factor: 4.174

3.  Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic.

Authors:  Lubna Patrawala; Tammy Calhoun; Robin Schneider-Broussard; Jianjun Zhou; Kent Claypool; Dean G Tang
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

4.  Cytogenetic characterization of ten malignant fibrous histiocytomas.

Authors:  H Schmidt; S Körber; R Hinze; H Taubert; A Meye; P Würl; H J Holzhausen; H Dralle; F W Rath
Journal:  Cancer Genet Cytogenet       Date:  1998-01-15

5.  Establishment and characterization of a new cell line, FPS-1, derived from human undifferentiated pleomorphic sarcoma, overexpressing epidermal growth factor receptor and cyclooxygenase-2.

Authors:  Michiyuki Hakozaki; Hiroshi Hojo; Michiko Sato; Takahiro Tajino; Hitoshi Yamada; Shinichi Kikuchi; Masafumi Abe
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

6.  Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.

Authors:  Hanna Berglind; Yudi Pawitan; Shunsuke Kato; Chikashi Ishioka; Thierry Soussi
Journal:  Cancer Biol Ther       Date:  2008-05-11       Impact factor: 4.742

Review 7.  p53: guardian of the genome and policeman of the oncogenes.

Authors:  Alejo Efeyan; Manuel Serrano
Journal:  Cell Cycle       Date:  2007-05-28       Impact factor: 4.534

8.  Chemically Defined and Xeno-Free Cryopreservation of Human Adipose-Derived Stem Cells.

Authors:  Melany López; Roni J Bollag; Jack C Yu; Carlos M Isales; Ali Eroglu
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

9.  Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53.

Authors:  Hind Hafsi; Daniela Santos-Silva; Stéphanie Courtois-Cox; Pierre Hainaut
Journal:  BMC Cancer       Date:  2013-03-20       Impact factor: 4.430

10.  CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity.

Authors:  Stefan Tanner; Alcide Barberis
Journal:  J Negat Results Biomed       Date:  2004-11-17
View more
  1 in total

1.  Characterization of a new glioblastoma cell line, GB-val4, with unusual TP53 mutation.

Authors:  Lisandra Muñoz-Hidalgo; Teresa San-Miguel; Javier Megías; Rosario Gil-Benso; Miguel Cerdá-Nicolás; Concha López-Ginés
Journal:  Hum Cell       Date:  2019-08-06       Impact factor: 4.174

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.